Sanofi is paying Regeneron $1 billion upfront to collaborate on four early-stage im | Sanofi is paying Regeneron $1 billion ...

Eli Lilly has shared detailed data from a phase 3 retatrutide trial, revealing that more than one-third of patients on the ...

When Xaira Therapeutics debuted in 2024 with a gobsmacking $1 billion in funding, a natural expectation would have been for a ...

Merck paid Daiichi $4 billion upfront in 2023 to partner on three ADCs. The FDA rejected a request for approval of one of the ...

As Foghorn digested the end of the Lilly partnership, the biotech said it was laying off 40% of its workforce, while “further ...

The Danish drugmaker is paying $300 million upfront to China’s Hengrui Pharma for a preclinical GLP-1/GIP dual receptor ...

Novartis is paying Abogen Biosciences $575 million upfront for an mRNA-encoded T-cell engager (TCE) that showed early clinical promise in autoimmune disease. The deal, which inclu ...

Merck touted a win for its anti-TL1A antibody in a phase 2b trial in patients with moderate to severe hidradenitis ...

A phase 3 trial of Boehringer Ingelheim’s survodutide in people with obesity and Type 2 diabetes has met its co-primary ...

Eli Lilly has tied its amylin-Zepbound combination treatment eloraTZP to 23.3% average weight loss in patients struggling ...

A more subdued volume of biopharma layoffs continued into the third quarter of 2026, validating predictions that the sector ...

Base editing biotech Beam Therapeutics is suing one of its newest rivals, alleging that the upstart company stole the secrets ...